Proportion who lost weight ( 5%) was 69% ( GLP1/GIP medication ) versus 57% (lower dose) versus 29% (PC)
Nevertheless, clinicians like Jenkinson caution that GLP-1s arent necessarily the answer for all patients living with obesity
BPC-157 has shown promise in helping protect dopamine and serotonin receptors and recovery benefits from certain neurological traumas
It is not intended for human consumption, diagnostic use, or therapeutic application
References Goldstein AL, Hannappel E, Sosne G, Kleinman HK
For example, if your regular day is Monday but you forgot and remember on Wednesday, inject on Wednesday and move your next dose to the following Wednesday